Vilon

Vilon is a dipeptide — lysine and glutamic acid, KE. The US National Library of Medicine files it under lysylglutamic acid with the code names AB-0 and AB-17 and a scope note calling it a geroprotective agent. Two residues is the floor for this whole concept: if a molecule this small can carry organ-specific instructions, the bioregulator hypothesis has room to stand. Vilon is where that bet was placed.

The proposed action is thymus-directed and immunological. KE was reported to affect interleukin-2 gene expression in splenocytes ( Bull Exp Biol Med 2002) and to alter thymocyte blast transformation via the sphingomyelin pathway ( Bull Exp Biol Med 2002), with later immunomodulating effects in cultured thymus cells ( Bull Exp Biol Med 2013). Naming a specific pathway is more than most of this family manages. It has not been independently confirmed.

No regulator recognises an indication for KE. Russian-language reports examined it in people with type 1 diabetes, looking at coagulation and fibrinolysis ( Adv Gerontol 2006) and at immune status and haemostasis by age ( Adv Gerontol 2007). These are among the very few human observations in the whole bioregulator literature — and they are uncontrolled reports of blood-test changes.

A dipeptide of two ordinary amino acids is not something laboratories screen for, so its absence carries no positive meaning. S0 still sweeps in substances without approval for human therapeutic use anywhere.

There is no toxicology package and no systematic adverse-event collection; the diabetes reports did not describe harm but were not designed to detect it. An agent proposed to modulate T-cell behaviour is not obviously appropriate in autoimmune disease or after transplant, and nothing published guides that judgement.

Dipeptides are cleaved efficiently by ordinary peptide-handling machinery, which makes the tissue-targeting claim hard to reconcile with physiology — a free lysine and a free glutamate are not a signal. No human measurement of intact KE in plasma exists.

A lyophilised powder. In the group's own experiments KE is one lane in a panel beside KED, AED and AEDG; in ageing skin fibroblasts all four suppressed MMP-9 and raised Ki-67 ( Bull Exp Biol Med 2016). When four supposedly organ-specific peptides behave alike in one dish, the specificity claim gets harder to sustain.

The founding claim appeared in 2000: female CBA mice given Vilon were reported to live longer, show greater endurance and develop fewer spontaneous tumours ( Khavinson, Anisimov et al., Bull Exp Biol Med 2000). The abstract states none of the quantities a reader needs — group sizes, dose, or how much longer. That is characteristic of the whole file: traceable to a publication that will not tell you the size of the effect it claims.

For deeper dives on this peptide, see:

• Vilon benefits and areas of interest
• Vilon side effects and safety context
• Vilon dosing concepts (educational)
• Vilon research and evidence overview

Has Vilon been shown to extend human lifespan? No. The longevity claim rests on rodent work from the developers' own laboratory.

Can a two-amino-acid molecule really target one organ? That is the central objection to the bioregulator idea. Lysine and glutamic acid are among the commonest residues in the diet; explaining how a pairing of the two would find the thymus and nowhere else is a problem the theory has not solved.

How does Vilon differ from Thymalin? Thymalin is a whole calf-thymus extract; Vilon is one defined synthetic dipeptide. Thymalin came first, and the short peptides were the attempt to find what in the extract was doing the work.

Is Vilon approved anywhere as a medicine? No — its National Library of Medicine record is a chemical index entry and says nothing about regulatory status.